ArticleBMC cancer2021

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.

Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.